

NLM Citation: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Substance Abuse Treatment Agents. [Updated 2014 May 20].

Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/



Substance Abuse Treatment Agents

Updated: May 20, 2014.

OVERVIEW

The Substance Abuse Treatment Agents are used in combination with structured relapse prevention interventions to treat alcohol, opiate, nicotine and other drug dependencies. These agents are usually not effective on their own and are considered adjunctive therapy to multidisciplinary substance abuse treatment.

The substance abuse treatment agents are generally classified based upon the specific dependency or abuse. Thus, drugs used for maintenance of alcohol withdrawal include disulfiram, acamprosate and naltrexone. Agents used for opiate withdrawal include buprenorphine, methadone and naltrexone. Agents for smoking cessation include nicotine and varenicline. The agents can also be classified as deterents (disulfiram, naltrexone), neurotransmitter analogues (acamprosate, varenicline), and agents that block withdrawal symptoms (buprenorphine, methadone, nicotine). Disulfiram has been linked to many cases of acute liver injury, some of which are severe and even fatal. The other substance abuse treatment agents have little or no hepatoxic potential unless taken in an overdose (buprenorphine).

The Substance Abuse Treatment Agents in clinical use include the following:

- Acamprosate
- Buprenorphine
- Disulfiram
- Methadone
- Nalmefene
- Naloxegol
- Naloxone
- Naltrexone
- Nicotine
- Varenicline